BACKGROUND: Airway smooth muscle (ASM) hyperplasia is a hallmark of asthma that is associated with disease severity and persistent airflow obstruction. OBJECTIVES: We sought to investigate whether fibrocytes, a population of peripheral blood mesenchymal progenitors, are recruited to the ASM compartment in asthma. METHODS: We assessed the number of fibrocytes in bronchial biopsy specimens and peripheral blood from subjects with mild-to-severe refractory asthma versus healthy control subjects. In vitro we investigated potential mechanisms controlling fibrocyte migration toward the ASM bundle. RESULTS: Fifty-one subjects with asthma and 33 control subjects were studied. In bronchial biopsy specimens, the number of fibrocytes was increased in the lamina propria of subjects with severe refractory asthma (median [interquartile range] number, 1.9/mm(2) [1.7/mm(2)]) versus healthy control subjects (median [interquartile range] number, 0/mm(2) [0.3/mm(2)], P < .0001) and in the ASM bundle of subjects with asthma of all severities (subjects with severe asthma, median [interquartile range] number, 3.8/mm(2) [9.4/mm(2)]; subjects with mild-to-moderate asthma, median [interquartile range] number, 1.1/mm(2) [2.4/mm(2)]); healthy control subjects, (median [interquartile range] number, 0/mm(2) [0/mm(2)]); P = .0004). In the peripheral blood the fibrocyte number was also increased in subjects with severe refractory asthma (median [interquartile range] number, 1.4 x 10(4)/mL [2.6 x 10(4)/mL]) versus healthy control subjects (median [interquartile range] number, 0.4 x 10(4)/mL [1.0 x 10(4)/mL], P = .002). We identified that in vitro ASM promotes fibrocyte chemotaxis and chemokinesis (distance of migration after 4.5 hours, 31 microm [2.9 microm] vs 17 microm [2.4 microm], P = .0001), which was in part mediated by platelet-derived growth factor (mean inhibition by neutralizing antibody, 16% [95% CI, 2% to 32%], P = .03) but not by activation of chemokine receptors. CONCLUSION: This study provides the first evidence that fibrocytes are present in the ASM compartment in asthma and that ASM can augment fibrocyte migration. The importance of fibrocytes in the development of ASM hyperplasia and airway dysfunction in asthma remains to be determined.
BACKGROUND: Airway smooth muscle (ASM) hyperplasia is a hallmark of asthma that is associated with disease severity and persistent airflow obstruction. OBJECTIVES: We sought to investigate whether fibrocytes, a population of peripheral blood mesenchymal progenitors, are recruited to the ASM compartment in asthma. METHODS: We assessed the number of fibrocytes in bronchial biopsy specimens and peripheral blood from subjects with mild-to-severe refractory asthma versus healthy control subjects. In vitro we investigated potential mechanisms controlling fibrocyte migration toward the ASM bundle. RESULTS: Fifty-one subjects with asthma and 33 control subjects were studied. In bronchial biopsy specimens, the number of fibrocytes was increased in the lamina propria of subjects with severe refractory asthma (median [interquartile range] number, 1.9/mm(2) [1.7/mm(2)]) versus healthy control subjects (median [interquartile range] number, 0/mm(2) [0.3/mm(2)], P < .0001) and in the ASM bundle of subjects with asthma of all severities (subjects with severe asthma, median [interquartile range] number, 3.8/mm(2) [9.4/mm(2)]; subjects with mild-to-moderate asthma, median [interquartile range] number, 1.1/mm(2) [2.4/mm(2)]); healthy control subjects, (median [interquartile range] number, 0/mm(2) [0/mm(2)]); P = .0004). In the peripheral blood the fibrocyte number was also increased in subjects with severe refractory asthma (median [interquartile range] number, 1.4 x 10(4)/mL [2.6 x 10(4)/mL]) versus healthy control subjects (median [interquartile range] number, 0.4 x 10(4)/mL [1.0 x 10(4)/mL], P = .002). We identified that in vitro ASM promotes fibrocyte chemotaxis and chemokinesis (distance of migration after 4.5 hours, 31 microm [2.9 microm] vs 17 microm [2.4 microm], P = .0001), which was in part mediated by platelet-derived growth factor (mean inhibition by neutralizing antibody, 16% [95% CI, 2% to 32%], P = .03) but not by activation of chemokine receptors. CONCLUSION: This study provides the first evidence that fibrocytes are present in the ASM compartment in asthma and that ASM can augment fibrocyte migration. The importance of fibrocytes in the development of ASM hyperplasia and airway dysfunction in asthma remains to be determined.
Authors: P R Johnson; M Roth; M Tamm; M Hughes; Q Ge; G King; J K Burgess; J L Black Journal: Am J Respir Crit Care Med Date: 2001-08-01 Impact factor: 21.405
Authors: Davinder Kaur; Ruth Saunders; Patrick Berger; Salman Siddiqui; Lucy Woodman; Andrew Wardlaw; Peter Bradding; Christopher E Brightling Journal: Am J Respir Crit Care Med Date: 2006-09-07 Impact factor: 21.405
Authors: Pascal Chanez; Sally E Wenzel; Gary P Anderson; Josep M Anto; Elisabeth H Bel; Louis-Philippe Boulet; Christopher E Brightling; William W Busse; Mario Castro; Babro Dahlen; Sven Erik Dahlen; Leo M Fabbri; Stephen T Holgate; Marc Humbert; Mina Gaga; Guy F Joos; Bruce Levy; Klaus F Rabe; Peter J Sterk; Susan J Wilson; Isabelle Vachier Journal: J Allergy Clin Immunol Date: 2007-04-09 Impact factor: 10.793
Authors: Kristian Nihlberg; Kristoffer Larsen; Anna Hultgårdh-Nilsson; Anders Malmström; Leif Bjermer; Gunilla Westergren-Thorsson Journal: Respir Res Date: 2006-03-29
Authors: Sara N Fischer; Jed K Johnson; Christopher P Baran; Christie A Newland; Clay B Marsh; John J Lannutti Journal: Biomaterials Date: 2010-09-26 Impact factor: 12.479
Authors: Brian J Lee; Stephen Atkins; Anna Ginter; Victor M Elner; Christine C Nelson; Raymond S Douglas Journal: Ophthalmic Plast Reconstr Surg Date: 2015 May-Jun Impact factor: 1.746
Authors: Stephen T Holgate; Hasan S Arshad; Graham C Roberts; Peter H Howarth; Philipp Thurner; Donna E Davies Journal: Clin Sci (Lond) Date: 2009-12-23 Impact factor: 6.124
Authors: R Saunders; A Sutcliffe; D Kaur; S Siddiqui; F Hollins; A Wardlaw; P Bradding; C Brightling Journal: Clin Exp Allergy Date: 2009-09-07 Impact factor: 5.018
Authors: D Kaur; F Hollins; R Saunders; L Woodman; A Sutcliffe; G Cruse; P Bradding; C Brightling Journal: Clin Exp Allergy Date: 2009-12-16 Impact factor: 5.018